Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
- 1.5k Downloads
Nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for advanced liver disease, type 2 diabetes (T2DM), and cardiovascular diseases. The prevalence of NAFLD in the general population is around 30 %, but it is up to three times higher in those with T2DM. Among people with obesity and T2DM, the NAFLD epidemic also is worsening. Therefore, it is important to identify early metabolic alterations and to prevent these diseases and their progression. In this review, we analyze the pathophysiologic mechanisms leading to NAFLD, particularly, those common to T2DM, such as liver and muscle insulin resistance. However, it is mainly adipose tissue insulin resistance that results in increased hepatic de novo lipogenesis, inflammation, and lipotoxicity. Although genetics predispose to NAFLD, an unhealthy lifestyle, including high-fat/high-sugar diets and low physical activity, increases the risk. In addition, alterations in gut microbiota and environmental chemical agents, acting as endocrine disruptors, may play a role.
KeywordsFatty liver Glucose intolerance De novo lipogenesis Lipotoxicity Gut microbiota Endocrine disruptors NASH
This work was supported by institutional grants of the CNR.
Compliance with Ethics Guidelines
Conflict of Interest
Chiara Saponaro is recipient of a research scholarship awarded by “Dottorato Pegaso Regione Toscana in Biochimica e Biologia Molecolare” she has no conflict of interest.
Melania Gaggini is recipient of a research fellowship awarded by Gilead.
Amalia Gastaldelli reports personal fees from Roche and Eli Lilly, and grants from Amylin-BMS-AstraZeneca.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.•Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60. This review analyzes the mechanisms relating NAFLD to CVD, including the role of ectopic fat accumulation, dyslipidemia, and lipotoxicity.PubMedCentralPubMedGoogle Scholar
- 7.•Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44. This article highlights the evidence that NAFLD is a multisystem disease and T2DM and CVD are factors that might determine interindividual variation in the development and progression of hepatic damage.PubMedGoogle Scholar
- 9.••Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–95. By analyzing the United Network for Organ Sharing/Organ Procurement and Transplantation Network database (more than 61,000 patients, 16% of whom received liver transplants), the authors found that NAFLD is the second leading cause of liver transplantation, but more importantly, it is the most rapidly growing indication for transplantation.PubMedGoogle Scholar
- 10.••Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23. These are the most recently published guidelines for the diagnosis and management of NAFLD.PubMedGoogle Scholar
- 13.Lattuada G, Ragogna F, Perseghin G. Why does NAFLD predict type 2 diabetes? Curr Diabetes Rep. 2011;11:167–72.Google Scholar
- 20.Portillo Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K (2014) High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. The Journal of Clinical Endocrinology and Metabolism 2014:jc20142739Google Scholar
- 22.••Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–51. This analysis of 1069 NAFLD patients participating in the PIVENS trial and NAFLD Database Study showed that both a personal and a family history of diabetes are associated with the presence of NASH and fibrosis.PubMedCentralPubMedGoogle Scholar
- 23.Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int : Off J Int Assoc Study Liver. 2013;33:1406–12.Google Scholar
- 26.••Margariti E, Deutsch M, Manolakopoulos S, et al. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol. 2012;25:45–51. This study showed that about one in eight NAFLD patients referred to a tertiary liver center has a normal BMI (<25 kg/m 2). These patients have higher levels of ALT/AST than overweight or obese NAFLD patients.Google Scholar
- 27.••Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine. 2012;91:319–27. In this analysis of NHANES III, the authors show that the prevalence of diabetes is higher in people with NAFLD, independent of obesity, although there is a higher prevalence among overweight/obese than lean subjects.PubMedGoogle Scholar
- 31.••Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:1389–97. These authors found that in patients with NAFLD, adipose tissue insulin resistance was associated with liver fibrosis, increased liver enzymes and TGs, and reduced HDL and adiponectin but found no association with NAFLD activity score.PubMedGoogle Scholar
- 36.••Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–35. This study measured DNL in vivo in subjects with NAFLD by using deuterated water and found that DNL increased up to three times compared with controls.PubMedGoogle Scholar
- 41.Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 1801;2010:299–310.Google Scholar
- 57.Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Med Cell Longev. 2014;2014:360438.Google Scholar
- 67.Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, Tichet J, Marre M, Balkau B, et al. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes. 2008;57:2253–7.PubMedCentralPubMedGoogle Scholar
- 68.•Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309. This article shows an association between the gene TM6SF2 and advanced hepatic fibrosis/cirrhosis independent of potential confounding factors (e.g., age, BMI, T2DM, and PNPLA3 rs738409 genotype).PubMedCentralPubMedGoogle Scholar
- 69.Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol. 2010;171:645–55.PubMedCentralPubMedGoogle Scholar
- 78.Liu WY, Luda J, Du XM, Sun JQ, Ge J, Wang RW, et al. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled tria. BMC Public Health. 2014;14:48.PubMedCentralPubMedGoogle Scholar
- 80.••Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab: TEM. 2013;24:537–45. Microbiotal factors and products may be involved in the regulation of insulin sensitivity and metabolic inflammation and are driving forces of hepatic steatosis.PubMedGoogle Scholar
- 83.Puddu A, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediat Inflamm. 2014;2014:162021.Google Scholar
- 84.••Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes. 2011;60:1838–48. This article discusses the epidemiologic links between chemical exposure and disorders of glucose metabolism, experimental data demonstrating chemical-induced changes in insulin action, and challenges facing the field of metabolic disruption, as well as approaches for addressing those challenges.PubMedCentralPubMedGoogle Scholar
- 86.Newbold RR. Impact of environmental endocrine disrupting chemicals on the development of obesity. Hormones (Athens). 2010;9:206–17.Google Scholar
- 94.•Lind PM, Zethelius B, Lind L. Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly. Diabetes Care. 2012;35:1519–24. Plasma concentrations of several phthalate metabolites were found to be related to diabetes prevalence, as well as to markers of insulin secretion and resistance.PubMedCentralPubMedGoogle Scholar
- 98.Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL: Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data. Clin Gastroenterol Hepatol 2014.Google Scholar
- 116.Otgonsuren M, Estep MJ, Hossain N, Younossi E, Frost S, Henry L, Hunt S, Fang Y, Goodman Z, Younossi ZM: A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol 2014.Google Scholar
- 132.Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29:139–53.PubMedGoogle Scholar